Search - tctmd.com

Displaying 121 - 140 of 23673

Sort: Relevancy | Date

News Conference News AHA 2016

Proton Pump Inhibitor Use Tied to Elevated Ischemic Stroke Risk

November 16, 2016

News Conference News AHA 2016

Racial Differences in How Patients Perceive CVD Risk Should Spur Rethink in Management

Yael L. Maxwell

November 16, 2016

News Conference News AHA 2016

Interatrial Shunt Device Shows Sustained Improvement in Heart Failure Patients With Preserved EF

November 16, 2016

Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Iron Deficiency and Chronic Heart Failure (EFFECT-HF)

Presentation AHA 2016

Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Iron Deficiency and Chronic Heart Failure (EFFECT-HF)

Presenter: Dirk J. van Veldhuisen

November 16, 2016

Intravenous Iron, Not Oral, Improves Functional Capacity in HF Patients

News Conference News AHA 2016

Intravenous Iron, Not Oral, Improves Functional Capacity in HF Patients

Michael O'Riordan

November 16, 2016

News Conference News AHA 2016

全国数据认为 PCI 在没有外科手术后备支援的中心“可能实施”

Yael L. Maxwell

November 16, 2016

News Conference News AHA 2016

Según Datos a Nivel Nacional, las PCI realizadas en Centros Sin Soporte Quirúrgico ‘Probablemente No Tengan Problemas’

Yael L. Maxwell

November 16, 2016

News Conference News AHA 2016

PCI at Centers Without Surgical Backup ‘Probably OK,’ Nationwide Data Suggests

Yael L. Maxwell

November 16, 2016

News Conference News AHA 2016

Dabigatran Reversal Agent’s Safety, Efficacy Affirmed With Updated Study Results

November 15, 2016

The REDUCE LAP Heart Failure Trial

Presentation AHA 2016

Transcatheter Intracardiac Shunt Device Provides Sustained Clinical Benefit at One Year in Heart Failure with Preserved or Mildly Reduced Ejection Fraction: The REDUCE LAP Heart Failure Trial

Presenter: David M Kaye

November 15, 2016

An OPen-label, Randomized, Controlled, Multicenter Study ExplorIng TwO TreatmeNt StratEgiEs of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy in Subjects With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention

Presentation AHA 2016

PIONEER Trial: An OPen-label, Randomized, Controlled, Multicenter Study ExplorIng TwO TreatmeNt StratEgiEs of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy

Presenter: Michael Gibson

November 15, 2016

Arterial Revascularization Trial (ART)

Presentation AHA 2016

Arterial Revascularization Trial (ART)

Presenter: David P. Taggart

November 15, 2016

News Conference News

You Can’t Blame Your Genes: Healthy Lifestyle Halves Genetic Risk of CAD

November 15, 2016

News Conference News AHA 2016

PCSK9 Inhibition and Other New Therapies for Lipid Modification: Good News and Bad

Michael O'Riordan

November 15, 2016

AEGIS-I Trial: The Safety and Tolerability of CSL112

Presentation AHA 2016

The Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Human ApoA-I, After Acute Myocardial Infarction: The ApoA-I Event reducingG in Ischemic Syndromes I Trial (AEGIS-I)

Presenter: Michael Gibson

November 15, 2016

GLAGOV Trial: Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound

Presentation AHA 2016

GLAGOV Trial: Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound

Presenter: Steven E. Nissen

November 15, 2016

FUnctional Testing Underlying REvascularization: The FUTURE trial

Presentation AHA 2016

FUnctional Testing Underlying REvascularization: The FUTURE trial

Presenter: Gilles Rioufol

November 15, 2016

News Conference News AHA 2016

局部麻醉对 TAVR 是安全的，让患者可以更快回家：荟萃分析

November 15, 2016

News Conference News AHA 2016

Local Anesthesia for TAVR Is Safe, Gets Patients Home More Quickly: Meta-analysis

November 15, 2016

News Conference News AHA 2016

La Anestesia Local durante la Realización de TAVR es Segura y los Pacientes se van Antes a Casa: Meta-análisis

November 15, 2016

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.